Heineken (HEIA)
Euronext Amsterdam · Netherlands · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 76.78 |
|---|---|
| 52-week range | 63.90 – 80.44 |
| Return, 1 month / 3 months | +8.8% / +0.8% |
| Return, 1 year / 3 years | +15.3% / −1.1% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 21.1% |
| Worst drawdown (1 year) | -18.7% |
| Average daily value traded | 50.83M EUR |
| Dividend yield | 2.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Heineken is a Dutch brewing company based in Amsterdam. It makes and sells beer and cider, including its namesake lager along with brands such as Amstel and Desperados. The company runs breweries and distributes its drinks to bars, restaurants, shops and wholesalers in many countries. Its customers range from individual drinkers to hospitality businesses and retail chains, and it also offers lower-alcohol and alcohol-free beer options.
The shares are listed on the Euronext Amsterdam in Netherlands under the code HEIA, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Heineken (HEIA) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 76.78 on 27 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 19 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 15.3% and over the last three months it rose 0.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.6% | ||
| From 52-week high | -4.2% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.8% | ||
| 6-month return | 17.8% | ||
| 12-month return, skipping the last month | 6.0% | ||
| Stability (higher is calmer) | 76 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.7% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 50.83M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.5% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.3% |
|---|---|
| 1 month | +8.8% |
| 3 months | +0.8% |
| 6 months | +17.8% |
| 1 year | +15.3% |
| 3 years | −1.1% |
| 5 years | −8.4% |
Signals
| 50-day / 200-day average | 72.49 / 70.70 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.25 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Aug 2026 | EUR 0.7600 |
| 27 Apr 2026 | EUR 1.1600 |
| 30 Jul 2025 | EUR 0.7400 |
| 23 Apr 2025 | EUR 1.1700 |
| 31 Jul 2024 | EUR 0.6900 |
| 29 Apr 2024 | EUR 1.0400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.